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BACKGROUND AND AIM OF THE PROJECT 
 
Up to fifty years ago the only property of the lymphocytes known was that they 
are mobile.  In the 1953 Arnold Rich, Baxley Professor of Pathology, concluded talking 
about the “small lymphocytes” than “literary nothing of importance is known regarding 
the properties of these small cells” (1).  At that time there was little evidence to convince 
anyone that small lymphocytes had immunological functions.  In 1959, Burnet wrote 
than: “An objective survey of the facts could well lead to the conclusion that there was 
no evidence of immunological activity in small lymphocytes” (2).  The view that Burnet 
expressed in the 1959 had to be updated a few years later, when an immunological role 
for small lymphocytes was unequivocally demonstrated by testing the ability of small 
lymphocytes from parental-strain rats to cause graft versus host (GVH) after injection 
into adult F1 hybrid rats.  Such inocula induced a vicious reaction in the recipients, with 
progressive wasting and death after a time depended on the cell dose.  For the first time 
was showed, that during the early stages of the resulting GVH reaction, the donor small 
lymphocytes enlarged and began dividing (3, 4).   
Only in the 1962, for the first time a role of small lymphocytes in the immune 
response was suggested (4).  The first persuasive evidence for the existence of two 
classes of lymphocytes came in the 1968 from the work of Mitchell and Miller (5) and 
the idea that thymus-derived (T) lymphocytes “helped” the development of marrow (B) 
lymphocytes was proposed for the first time by Mitchison in the 1971 (6). 
Since these early studies, the lymphocyte has risen to become one of the most 
studied of all mammalian cells.  Tremendous progresses achieved in developmental, 
cellular and molecular immunology has been achived in the past 20 years, largely due to 
studies using the mouse model system and the arrival of molecular genetics.   
The generation in 1989, for the first time of a knockout animal by Thompson and 
colleagues (7), revolutionized the studies of mammalian physiology, and immunologist 
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were among the first to take advantage of the new approach.  The technology was 
rapidly and widely adopted and hundreds of genetically designed knockout mice are 
now available to help us understand the roles of specific gene in development of the 
immune system as well as in disease situation such as autoimmunity, infections and graft 
rejections (8; http://www.informatics.jax.org/).  
Despite the abundant knowledge that is now available in the immunology field, 
surprising little is known, however, about immunity to infection.  We know about the 
generation of antibody diversity, the structure of surface molecules of lymphocyte 
subsets, and the role of the major histocompatibility complex (MHC) in cell cooperation 
and antigen recognition.  However, we know little about the function of most of these 
molecules and cell subsets.  
To study immunity to infection is undeniable difficult due to the high complexity 
of the host-environment relationship and the interaction between different cells and 
components of the organism.  In this contest also the forward-genetic studies in mice 
only in few case have proven to be have clinical relevant implication.  The difficulty in 
translating genetic discoveries made in mice into real clinical benefits might reflect 
intrinsic molecular differences between species, due to phylogenical distances that 
separate human and mice (9).  Nevertheless, mice studies provided us a huge number of 
candidate genes for human studies.   
Immunodeficiency disorders are a diverse group of illnesses that increase 
susceptibility to infection (10, 11).  Primary immunodeficiencies, naturally occurring 
defects of the immune system, were not identified until after the introduction of 
antibiotics because of high morbidity and mortality of those affected early in life (10).  
They are mostly congenital and hereditary, with broad clinical presentations that reflect 
the complexity of the immune system and the underlying genetic defects.  Combined 
immunodeficiencies (CIDs) are a heterogeneous group of disorders characterized by 
defects in T-cell development and/or function, associated with abnormal function or 
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development of B and NK cells (12).  Patient with defects that involve T cells do not 
have adequate cellular immune responses and are predisposed to developing 
opportunistic infections (13).  Severe combined immunodeficiencies (SCID) represent 
the most severe form of CIDs, and have an overall frequency of approximately 1 in 
75,000 births.  SCID conditions share the characteristic of a profound block in T cell 
differentiation (14, 15) and are lethal within the first year of life because of absent T 
cell–mediated immunity.  Most forms of SCID are associated with molecular alterations 
of genes selectively expressed in hematopoietic cells and implicated in cell 
differentiation/activation process.  The only SCID condition caused by an alteration in a 
gene not expressed in the hematopoietic compartment is the human Nude/SCID 
phenotype, which is caused instead by a thymic defect (16-18) (see Chapter II of this 
Thesis). The molecular defects in many case of SCID have yet to be identified.   
 This thesis reports the results I obtained during the Dottorato di Ricerca in 
“Accrescimento, Sviluppo e Riproduzione dell’uomo” (XVIII Cycle) from 2002-2006.  
During the past 4 years, my research has been focused in the molecular and functional 
characterization of patients with primary immunodeficiencies.   
Based upon previous studies performed in Prof. Pignata’s laboratory, which 
characterized an atypic case of X-linked SCID phenotype associated with growth 
hormone hyporesponsiveness (19) and identified the first case of human Nude/SCID 
phenotype (17), I set out to define the biochemical and molecular mechanisms of the 
immune response regulation and to elucidate the basis of the interplay between the IS 
and other systems of the organism by evaluating the perturbations of this interplay in 
patients with congenital immunodeficiency (CID). 
In particular the following three lines were developed: 
 
- Role of the interaction between Endocrine System and Immune System in 
the physiology of the immune response in particular functional 
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interactions between common gamma chain and Growth Hormone 
Receptor signaling elements were examined. 
 
- Molecular and clinical characterization of the human Nude/SCID 
phenotype and identification of clinical signs suggesting a previously 
unappreciated functional rule of FOXN1 transcription factor in the 
development and differentiation of the central nervous system. 
 
- Role of the Interleukin-12/Interleukin-12R (IL-12/IL12R) axis in diseases 
associated with predominant T-helper 2 (Th2) activity 
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CHAPTER 1 
 
EVIDENCES OF A PREVIOUSLY UNAPPRECIATED FUNCTIONAL 
INTERACTIONS BETWEEN COMMON GAMMA CHAIN AND GROWTH 
HORMONE RECEPTOR SIGNALING ELEMENTS 
 
Introduction 
 
The most common form of Severe combined immunodeficiency  accounting for 
approximately half of all cases with an estimated incidence of 1:150000 to 1:200000 live 
births is the X-linked SCID (X-SCID) (20, 21).  This form of SCID is characterized by 
absence of mature T and NK lymphocytes and absent immunoglobulin synthesis, despite 
the presence of a normal or sometime elevated number of B-cells.  In X-SCID patients 
T-cells are absent not only in the peripheral blood but also in the central and peripheral 
lymphoid organs suggesting an early block in the T-cells differentiation pathway in this 
disease (22).  Furthermore, although peripheral B-cells exhibit a normal phenotype, X-
SCID patients B-cells are not functional, even after T-Cell reconstitution by means of 
bone marrow transplantation (23, 24).  These observations and data from X-
chromosome inactivation studies in obligate carriers, showing a skewed pattern of 
inactivation in B cells, as well as in T and NK cells, suggested that an intrinsic defect of 
the B-cell compartment is also present in this form of SCID (25, 26).  
Atypical cases of X-SCID were reported, including forms with progressive loss of 
T-cell number and function, leading to death during childhood (27, 28).  A unique 
patient, in whom a reverse mutation in an early T-cell progenitor, with normal amounts 
of circulating T cells, was also described (29).  In many cases the clinical and 
phenotypic heterogeneity of X-SCID remain poorly understood.   
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The gene responsible for X-SCID is IL2RG that encodes for the common cytokine 
receptor γ chain (γc), a member of the cytokine receptor class 1 superfamily.  The 
molecule represents a shared component of several cytokines receptors critical for the 
development and function of lymphocytes such as Interleukin- (IL-) 2, IL-4, IL-7, IL-9, 
IL-15 and IL-21 (21).  Cytokines regulate cellular activation, proliferation, 
differentiation, and survival.  A common future for cytokines is that their receptors lack 
intrinsic tyrosine kinase activity and that they use the Janus kinase (JAK)/Signal 
transducer and activator of transcription (STAT) signaling pathway to mediate gene 
activation or repression.   
The JAK/STAT pathway is one of a handful of pleiotropic cascades used to 
transduce a multitude of signals for development and homeostasis in mammalians (30).  
JAKs are cytoplasmic tyrosine kinases pre-associated with the intracellular domains of 
cytokine receptors.  The binding of the ligand to the specific receptors results in 
dimerization of receptor subunits, thus increasing the local concentration of JAKs 
bringing these kinases into close proximity, allowing their trans-phosphorylation and 
activation.  The activated JAKs initiate the signal transduction cascade by 
phosphorylation of tyrosine motifs present in receptor cytoplasmic domains and in 
receptor-associated proteins.  Phosphotyrosine-containing motifs in receptor cytoplasmic 
domains act as docking sites for many signaling proteins, including STATs.  STAT 
proteins are also phosphorylated on a conserved tyrosine residue.  Tyrosine 
phosphorylation induces STATs activation resulting in dissociation from the receptor, 
dimerization and acquisition of high-affinity DNA-binding activity.  After activation 
STATS translocate to the nucleus, where they bind to gene promoters and activate 
transcription (21, 30-32).  
There are four members JAKs (JAK1-3 and TYK2) and seven STAT proteins 
(STAT1-4, STAT5a, STATb and STAT6) (32).  All γc-containing cytokine receptors 
can activate JAK1 and JAK3 (33-35).  Although many cytokines can induce activation 
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of JAK1, only cytokines with a γc-dependent receptor can induce activation of JAK3 
(21).  JAK3 is selectively associates with γc (36).  STAT 1, STAT3 and STA5 are 
activated after binding of the specific ligand to γc-dependent cytokine receptors.  
Whereas JAK3 can only phosphorylate STAT3 and STAT5, JAK1 can phosphorylate  
STAT1, STAT3, and STAT5, but only in the presence of an activated JAK3 (37).  This 
would indicate that γc-associate JAK3 activates JAK1 which is then able to induce 
activation of the target STATs molecules (38).   
To our knowledge, an extrahematopoietic role of γc has not yet been 
demonstrated, although the abundance of the protein in non-hematopoietic cells would 
imply additional functions for this element (39, 40). 
We previously reported on a patient affected with a X-linked Severe Combined 
Immunodeficiency (X-SCID) who received a bone marrow transplantation (BMT) late at 
5.2 years of age.  In this patient, short stature became evident, and a peripheral growth 
hormone (GH) hyporesponsiveness associated with abnormalities of the protein 
phosphorylation events that occur following GH receptor (GHR) stimulation were 
demonstrated.   
The GHR was the first identified member of the cytokine receptor class 1 
superfamily, which includes receptors for Erythropoietin (EPO), Granulocyte colony 
stimulating factor (G-CSF), Granulocyte-macrophage colony stimulating factor (GM-
CSF), Interleukins- (IL-) 2-7, IL-9, IL-11, IL-12 and many other cytokines.  Due to the 
lack of intrinsic kinase activity, members of the cytokine receptor superfamily recruit 
and/or activate cytoplasmic tyrosine kinases to relay their cellular signal.  The Janus 
associated kinase 2 represents the predominant non receptor tyrosine kinase required for 
the initiation of GH signal transduction upon ligand binding to the receptor (41, 42).  
However, GH also stimulates tyrosine phosphorylation of JAK1 (43, 44) and JAK3 (34) 
in certain cell lines.  Signal transduction through GHR also involves a wide array of 
molecules, such as STAT1, 3 and 5, Extracellular regulated kinase (ERK) 1 and 2 and 
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Phosphatidylinositol-3 kinase-protein kinase B  (42).  Activation of STAT5b is 
considered a prominent event in GH signaling and is crucial for the regulation of 
transcription of GH-responsive genes, including the gene encoding for insulin-like 
growth factor-I (IGF-I), which mediates many of the GH biological functions (45-47).  
In our previous study, mutational screening and expressional analysis failed to reveal 
any molecular alteration of GHR, JAK2 and STAT5A/B genes in the patient with X-SCID 
and peripheral GH hyporesponsiveness (19).   
Since we hypothesized a role for the γc chain in GHR signaling, in this study, we 
evaluate the functional interaction between GHR and the common γ element in either 
freshly isolated or Epstein-Barr virus (EBV) transformed lymphocytes from X-SCID 
patients and healthy subjects.  In particular, the functional response to GH stimulation, 
the pattern of GHR induced protein tyrosine phosphorylation and GH induced 
translocation from the cytoplasm to the nucleus of STAT5 were evaluated.  We 
demonstrate the existence of a previously unappreciated functional interaction between 
γc and GHR.  This interaction leads to the activation and intranuclear translocation of 
STAT5b protein.   
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Materials and Methods 
 
Reagents 
 
Recombinant human growth hormone (rGH) was obtained from Serono (Saizer® 
4).  The enhanced chemiluminescence kit (ECL) was purchased from Amersham 
Biosciences.  The antibodies anti-STAT5b, anti-STAT5a, anti-STAT1, anti-STAT3, 
anti-ERK (recognizing both ERK1 and ERK2), anti-phosphotyrosine ERK, anti-GHR 
and anti-γc and the monoclonal-antibodies anti-phosphotyrosine were purchased from 
Santa Cruz Biotechnology (Santa Cruz).  The antibody anti-JAK2 was purchased from 
Cell Signaling Technology.  The neutralizing IgG1 anti-γc MAB was purchased from 
R&D Systems.  An IgG1 isotype matched anti-CD3 MAB (Leu 3, UCHT1 clone) was 
purchased from Becton Dickinson.   Epidermal Growth Factor was purchased from BD 
Bioscience and used at the concentration of 100 ng/ml.  Acrylamide and bisacrylamide 
were from Gibco.  Prestained molecular weight standards were from BIORAD.  Except 
where noted, other reagents were of either reagent or molecular biological grade from 
Sigma.   
 
EBV stock preparation 
 
 EBV-trasformed B95-8 marmoset cell line were grown in RPMI 1640 medium, 
supplemented with 10% fetal bovine serum (FBS).  The cultures are maintained for 12-
15 days.  After centrifugation for 5 min at 1500rpm, the supernatant was filtered though 
a 0.22-µm membrane (Millipore) and stored a 4 ºC until use. 
 
Cells separation  
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Mononuclear cells (PBMC) were obtained from 4 X-SCID patients in wich γc 
mutations led to the absence of protein expression and normal donors heparinized 
peripheral blood by Ficoll-Hypaque (Biochrom) density gradient centrifugation.  
Briefly, after dilution 1 to 1 with PBS ph 7.4 blood samples are carefully laid on Ficoll-
Hypaque at a 2 to 1 ratio.  After centrifugation at 1500 rpm for 30 min at 18-20 °C in a 
SORVALL® Legend RT centrifuge, the upper layer of plasma was draw off and the 
lymphocyte layer transfer to a clean centrifuge tubes.  Lymphocytes were then 
suspended in 3 volume of PBS, tubes centrifuged at 1500 rpm for 15 min at 18-20 °C 
and the supernatant removed.  The wash step was repeated two times.  Cells were 
suspended in a know volume of complete media (RPMI 1640 media supplemented with 
10% FBS, 2 mmol/L L-glutammine, and 50 µg/ml gentamycine, all from Gibco) and 
count using a hemocytometer (Hausser Scientific).  
NIH 3T3 fibroblasts were used in a few experiments. 
 
Immortalization of lymphocytes 
 
Upon informed consent, lymphoblastoid cell lines (BCLs) were generated by 
Epstein-Barr virus immortalization of patients and controls PBMC using standard 
procedures (48).  Briefly, immortalization was achieved by mixing 3x106 PBMC of each 
subjects suspended in 3 ml of RPMI complete medium  with 1 ml of active EBV 
supernatant in presence of 2 µg/ml cyclosporin A (Sigma) in 14 ml Polypropylene 
round-bottom tubes (Falcon).  After 24 h cells were washed two times with worm PBS, 
count and put in culture in a 96 wells tissue plate (105 cells/well) in fresh media 
containing 1 µg/ml cyclosporin A.  Continuous cellular passages were made every 3 or 4 
days (twice per week) by exchanging an half volume of cultivating cell suspension with 
fresh medium.  Growing cells were moved in 25 cm2 tissue culture flask (Corning).  
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Cells were maintained in RPMI 1640 (Biochrom) supplemented with 10% fetal 
bovine serum (Gibco), 2 mmol/L L-glutammine (Gibco), and 50 µg/ml gentamycine 
(Gibco), and cultured at 37°C, 5% CO2 or frozen in 10% dimethylsulfoxide (DMSO) 
and kept in liquid nitrogen..  
 
Transduction of Lymphocytes 
 
 pGC2Rγ retroviral vector (49) was used to transduce X-SCID BCLs with WT γc 
as previously described (50). 
The transduction procedure was initiated by performing a phosphate depletion 
step for 3-12 hr at 37°C prior to the transduction start point by pelleting the cells, 
washing the cells in the RPMI 1640 phosphate-free medium, and resuspending the cells 
at 1 x 106/ml (2 ml per well, in 6-well plates) in RPMI 1640 phosphate-free medium 
supplemented with 5% heat-inactivated FBS and rIL-2 at 200 U/ml.  The phosphate-
starved cells were subsequently exposed to the retroviral vector by the addition of 
supplemented supernatant, followed by centrifugation at 32°C for 60 min and incubation 
for 12 hr at 32°C in a 5% CO2 incubator. At the end of the transduction, the 
lymphocytes were pelleted, washed, and cultured at 1 x 106 cells per ml in AIM-V 
media supplemented with 5% fetal bovine serum and rIL-2 at 200 units/ml.  
Lymphocyte viability and number were determined using trypan blue exclusion.  
Transduced cells were selected in the neomycin-analogue G418 (Cellgro®). 
 
Proliferative assay 
 
BCLs (1 X 105 cell/200 µl well) were cultured triplicate in 96-well U-bottomed 
microtiter plates (Falcon®, Becton Dickinson) with or without rGH at reported 
concentrations for 4 days.  The proliferative response was evaluated by thymidine 
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uptake from cultured cells pulsed with 0.5 µCi [3H]thymidine (Amersham International) 
8 h before harvesting (51). In neutralization experiments, control EBV cells were 
preincubated with the neutralizing MAB 284 at the concentration of 6 ng/ml for 3 h or 
with the IgG1 isotype matched Ab (Leu 3). 
 
Flow cytometry 
 
The expression of the γc chain (CD132) was detected using specific rat antibodies 
phycoerythrin-(PE-) conjugated (Becton-Dickinson) by direct immunofluorescence.  
After washing in PBS, 1X106 cells were suspended in 100 ml of staining buffer (PBS + 
2% FBS) and incubated for 10 min on ice in presence of 2 µl unlabeled mouse IgG.  
Without washing 2 µl of PE-conjugated rat isotype control antibodies (Becton-
Dickinson) or 2 µl of PE-conjugated anti-CD132 specific antibodies were add to the 
cells.  After 30 min of incubation on ice all samples were washed in PBS and acquired 
on the LSRII flow cytometer (Becton-Dickinson) using DIVA software for acquisition 
and FlowJo software (TreeStar) for the data analysis. 
The expression of GHR was detected using specific rabbit antibodies (Santa Cruz) 
by indirect immunofluorescence using a second-step incubation with a fluorescein-
(FITC-) conjugated donkey anti-rabbit antibodies  (Pierce).  After washing in PBS, cells 
were incubated for 20 min with the specific antibodies and 30 min with secondary 
antibodies.  After staining, all samples were washed in PBS and acquired on the 
FACScan flow cytometer (Becton-Dickinson) using Lysis I software. 
 
Cell stimulation and protein extraction 
 
Prior to hormone treatment, the cells were made quiescent through incubation in 
RPMI 1640 minus serum for 8-12 h.  GH was used at 37°C at a concentration of 500 
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ng/ml in RPMI 1640 for the reported time.  Incubations were terminated by washing 
cells with ice cold phosphate-buffer saline  (PBS; BioWhittaker) followed by 
solubilization in 100 µl of lysis solution containing 20 mM Tris (pH 8), 137 mM NaCl, 
1% Nonidet P-40, 10 mmol EDTA, 1 mM phenylmethylsulfonylfluoride, 1 mM sodium 
orthovanadatum (Na3VO4), 5 µg/ml leupeptin and 5 µg/ml aprotinin.  The cell lysates 
were stored at -80°C for Western blot analysis.  Nuclear extracts were prepared by the 
method of Andrews et al. (52) and were subsequently mixed with sample buffer. 
 
Western blot 
 
Immunoblotting using phosphotyrosine monoclonal antibody was performed as 
previously reported (19).  Immunoblotting using specific antibody was performed 
according to the vendors protocols.  In brief, protein samples separated by SDS-PAGE 
were transferred onto Mixed Cellulose Esters membranes (Immobilon-NC Mixed 
Cellulose Esters 0.45 µm; Millipore).  The membrane was incubated at room 
temperature for 1 h in blocking buffer consisting of 10% Bovin Serum Albumin (BSA) 
in wash buffer (10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween 20).  The membrane 
was then washed three times in wash buffer and incubated 1 h at room temperature or 
overnight at 4°C with the specific antibody.  The membrane was then washed three 
times and an appropriate IgG horseradish peroxidase-conjugated secondary antibody 
was used for the second incubation.  After further washings, the membrane was 
developed with ECL developing reagents, and exposed to x-ray films according to the 
manufacturer’s instructions (Amersham Biosciences).   
 
Confocal microscopy 
 
 17 
After appropriate stimulation, quiescent cells were rinsed in ice cold PBS and 
fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 min at room 
temperature.  After 4 rinses of 5 min in PBS, the cells were centrifuged in a Shandon 
Cytospin III (Histotronix Inc.) onto glass slide and permeabilized by incubation in a 
0.2% Triton X-100 solution for 20 min.  The cells were then incubated for 1 h at room 
temperature with rabbit antibodies against STAT5b diluted 1:100 in PBS containing 1% 
BSA.  After 4 washings for 5 min in PBS, the cells were incubated for 1 h at room 
temperature with a 1:200 dilution of Fluorescein isothiocyanate (FITC)-conjugated 
donkey anti-rabbit IgG (Pierce Biotechnology Inc.) in PBS.  After washing in PBS, the 
glass slides were mounted under a coverslip in a 50% glycerol/50% PBS solution.  The 
slides were analyzed by laser scanning Confocal microscopy, using a Zeiss LSM 510 
version 2.8 SP1 Confocal System. 
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Results 
 
Effect of GH on the proliferative response of EBV transformed cell lines from normal 
subjects and γc negative X-SCID patients 
 
It has been reported that GH enhances EBV transformed cell lines proliferation in 
vitro, its effect being direct and not mediated by IGF-I (51).  Thus, to evaluate a 
biological role of γc in GHR signaling, we evaluated the response of EBV transformed 
lymphocytes (BCLs) from γc negative X-SCID patients and normal controls to GH 
stimulation.  As shown in Fig. 1.1A, GH enhanced proliferation of BCLs of control 
subjects in a dose-dependent fashion.  Significant enhancement of [3H]thymidine uptake 
was observed at a GH concentration of 50 ng/ml, and the maximal effect was achieved 
at 200 ng/ml.  In contrast, γc negative BCLs didn’t respond at any GH concentration.  To 
rule out that the observed phenomena were due to different numbers of the receptor 
molecules on the cell membrane, GHR expression was evaluated by flow cytometry 
analysis on control’s and patient’s cells (Fig. 1.1B).  No difference was found in the 
mean fluorescence intensity (130.99 + 28.19 vs 139.88 + 33.49 in patients and controls, 
respectively; p = NS) and in the percentage of positively stained cells (99.6 vs 99.7% 
and 99.8 vs 99.9%, respectively).  
Moreover, to demonstrate a link between the γc and GHR, we used a neutralizing 
MAB in the proliferative assay.  As shown in the Fig. 1.1C, the neutralizing MAB 
inhibited by 64% the proliferative response to GH.  A non specific effect of the Ab was 
ruled out, since the IgG1 anti-CD3 isotype matched Ab was ineffective in inhibiting cell 
proliferation. 
To define whether PI3 kinase had a role on GH-induced cell proliferation of BCLs 
to GH, the kinase inhibitor wortmannin was used. As shown in Fig. 1.1D, no inhibitory 
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effect was appreciable. By contrast, in the positive control wartmannin was able to 
inhibit fibroblast proliferation to EGF by 85%. 
To ascertain whether γc was linked to GHR, we then assessed by confocal 
microscopy the plasma membrane expression of these 2 molecules.  As shown in Fig. 
1.1D, by indirect immunofluorescence using specific antibodies, as previously detailed, 
co-localization of γc and GHR was observed on the cell surface of normal BCL cells. 
 20 
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Figure 1.1.  In vitro effect of GH stimulation on proliferation of X-SCID patients’ and controls’ EBV 
cell lines and membrane localization of GHR and γc. (A) Lymphoblastoid cell lines (BCLs) were 
generated by Epstein-Barr virus immortalization of patients’ and controls’ PBMC using standard 
procedures and cultured in the presence of various concentrations of GH for 4 days.  Cultures were 
pulsed with [3H]thymidine for the final 8 h and radioactive incorporation counted.  Results are 
expressed as the increase of cpm from the background.  Vertical bars indicate 1 SD. (B) Flow 
cytometry analysis indicating that the expression levels of GHR are comparable in controls and 
patients.  (C) Control BCLs were pretreated with medium alone (closed bars) or with the neutralizing 
MAB 284 (open bars) at the concentration of 6 ng/ml for 3 h, and then cultured for 4 days in the 
presence of GH at the concentration of 200 ng/ml.  As isotype-matched IgG1 control Ab, anti-CD3 Leu 
3 was used.  Cultures were processed as previously described. (D) Control BCLs were pre-treated for 1 
h with medium alone or with wortmannin at the concentration of 100 nM, and then stimulated with 50, 
100, 200 or 400 ng/ml GH, as indicated. As a positive control, fibroblasts were cultured in the presence 
of EGF. E, Gamma chain co-localizes with GHR.  Normal BCL cells were double labelled with anti-γc 
(left) and anti-GHR (center) antibodies.  Confocal microscopic analysis indicates a plasma membrane 
localization for both molecules.  The yellow colour in the merge, (showed on the right), indicates areas 
of co-localization of the two proteins. 
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Pattern of protein tyrosine phosphorylation induced through GHR engagement in 
patients and controls cells 
 
We next investigated the overall signal transduction properties of patients and 
control BCLs following GHR ligation by analysing the number and the timing of the 
proteins phophorylated on tyrosine residues.  Fig. 1.2 illustrates a representative 
immunoblot with anti-phosphotyrosine antibodies of whole cell lysates from patient’s 
and control’s BCLs following stimulation with GH for 5, 15 or 30 min.  In contrast to 
what observed in control cells, in patients GH stimulation failed to induce 
phosphorylation of proteins approximately of 90 kDa, presumably corresponding to 
STATs molecules involved in the signal transduction through GHR.  This pattern of 
protein tyrosine phophorylation was also observed in freshly isolated PBMC from a 
healthy subject and a patient stimulated with the same concentration and for the same 
time, thus confirming the observation on BCLs (data not shown).   
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Figure 1.2.  Pattern of protein tyrosine phosphorylation induced through GHR engagement.  BCLs 
from X-SCID patients and healthy subjects were starved of serum for 8-12 h and then stimulated with 
GH (500 ng/ml) at 37°C for the indicated time.  Stimulation was stopped with cold PBS and BCLs were 
resuspended in lysis buffer.  After SDS-PAGE and Western blot, membranes were incubated with anti-
phosphotyrosine antibodies.  
 24 
GHR signal transduction pattern 
 
The 3 main signal modules by which signal transduction through GHR occurs 
involve Mitogen-activated protein kinases/ERK1 and 2, JAK2, STAT1, STAT3 and 
STAT5 and the Phosphatidylinositol-3 kinase-protein kinase B signalling (42).  
To evaluate whether the γc was involved in the GHR signaling events, we first 
focused on STAT5 molecule. As shown in Fig. 1.3, in control’s BCLs, tyrosine 
phosphorylation of STAT5 was evident, with a peak of activity observed between 5 and 
15 min after GH stimulation.  By contrast, in patient’s BCLs no phosphorylation of 
STAT5 was detectable after stimulation.  In all cell lines examined, STAT5b and 
STAT5a protein expression was comparable in patients and controls.   
To define whether the blockage in GHR signaling was specific of STAT5 or 
involved other molecules as well, we then studied JAK2, STAT1, ERKs and STAT3 
phosphorylation (Fig. 1.4, A, B, C, and D).  No difference in the phosphorylation events 
between patient’ and control’ BCLs was appreciable.  As shown, the expression of the 
molecules was comparable in control and patient cells. 
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Figure 1.3.  STAT5 phosphorylation induced through GHR stimulation.  rGH stimulation failed to 
induce STAT5 tyrosine phosphorylation in γc negative BCLs.  BCLs from X-SCID patients and 
healthy subjects were starved of serum for 8-12 h and then stimulated with GH (500 ng/ml) at 37°C for 
the indicated time.  After SDS-PAGE and Western blot, membranes were incubated with anti-pSTAT5, 
anti-STAT5b or anti-STAT5a antibodies.  
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STAT5 nuclear translocation after GHR triggering 
 
Recently it has been reported that tyrosine phosphorylation of STATs molecules 
was not sufficient for the activation of the protein (53, 54).  Because the activated 
STAT5 translocates into the nuclei, confocal microscopy was initially used to test the 
subcellular localization of STAT5b in control and patient γc negative cells under resting 
conditions and after stimulation with GH.   
Patients and controls BCLs were stimulated with GH for 30 min, fixed and 
incubated with antiserum against STAT5b.  As shown in Fig. 1.5, under basal conditions 
all cells displayed fluorescent staining of the cytoplasm indicating the presence of 
STAT5b in this compartment, and only a negligible staining of nucleus indicating 
absence of STAT5b in this compartment.  Stimulation with GH for the time indicated 
induced nuclear translocation of STAT5b in the control’s BCLs, as demonstrated by the 
marked increase in STAT5b immunoreactivity within the nucleus and not in γc 
negative BCLs.   
We next evaluated by immunoblot of nuclear and cytoplasmic extracts the amount 
of STAT5b translocation and compared it with the tyrosine phosphorylation of the 
molecule.  As shown in Fig. 1.6, in controls cells GH stimulation determined a rapid 
increase of nuclear STAT5b amount.  The translocation occurred early being evident 5 
min after GH stimulation.  Moreover, it still persisted 30 min after the stimulation.  The 
translocation paralleled the amount of the tyrosine phosphorylated form of the protein 
into the nuclei.  This was inversely correlated with the amount of the cytoplasmic form 
of the molecule.  However, after 30 min the reconstitution of the cytoplasmic aliquot 
became evident.  In the patient cells no changes were observed. 
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Figure 1.5.  STAT5b subcellular localization.  X-SCID patients and healthy subjects control cells were 
cultured in the absence or presence of 500 ng/ml rGH for 30 min at 37°C.  Unstimulated or stimulated 
cells were analyzed by Confocal microscopy for STAT5b (green) distribution in the cell, focusing 
particularly on whether this protein was present in the nuclei. 
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Figure 1.6.  Nuclear fraction of the overall STAT5b amount and of the phosphorylated form of STAT5 
in resting or rGH stimulated BCLs.  Patient and control BCLs were stimulated with rGH (500 ng/ml) or 
medium alone at 37°C for the indicated time.  Stimulation was stopped with cold PBS and nuclei were 
isolated as described in Materials and methods.  After SDS-PAGE of nuclear and cytoplasmic extracts 
and Western blot, membranes were incubated with anti-STAT5b or anti-pSTAT5 antibodies.   
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GH-induced signalling and STAT5b nuclear translocation in X-SCID EBV cells 
transduced with WT γc gene 
 
We next evaluated whether reconstitution of X-SCID cells with WT γc led to a 
functional recovery.  As shown in Fig. 1.7A, pGC2Rγ cells expressed γc at a normal 
extent.  These cells proliferated in a comparable fashion to control cells following GH 
stimulation (Fig. 1.7B).  Moreover, in WB experiments using an anti-phospho STAT5 
antibody, a phosphorylation of the molecule was observed in pGC2Rγ cells (Fig. 1.7C).  
Finally, in reconstituted cells, GH stimulation induced a normal nuclear translocation of 
STAT5b, as shown in Fig. 1.7D. 
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Figure 1.7.  GHR signaling in 
patient BCLs reconstituted 
with WT γc (pGC2Rγ cells). 
(A) Membrane expression of 
γc in patient or pGC2Rγ cells 
by flow cytometry. 
(B) Proliferative response in 
control, patient or 
reconstituted BCLs.  Cells  
were cultured in the presence 
of various concentrations of 
GH for 4 days and pulsed with 
[3H]thymidine as previously 
described.  Results are 
expressed as increase of cpm 
from the background.  
Vertical bars indicate 1 SD. 
(C) STAT5 phosphorylation 
induced through GHR 
stimulation for the indicated 
time in pGC2Rγ cells. 
Membranes were incubated, 
as indicated, with anti-
pSTAT5, anti-STAT5a or 
anti-STAT5b antibodies.   
(D) STAT5b subcellular 
localization through confocal 
microscopy analysis in control 
or pGC2Rγ cells unstimulated 
or stimulated with 500 ng/ml 
rGH for 30 min at 37°C.  
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Discussion 
 
In the present study, we examined a potential role of the common cytokine 
receptor γ chain (γc) in GHR signaling using BCLs from healthy control subjects and γc 
negative X-SCID patients.   
At a functional level, GH enhanced proliferation of control BCLs in a dose 
dependent fashion.  By contrast, the functional response to GH of γc negative patients 
BCLs was severely impaired despite a comparable cellular expression of GHR 
molecules.    
The overall signal transduction properties of GHR in X-SCID patients and control 
BCLs following GH stimulation was also examined by analysing the pattern of protein 
tyrosine phosphorylation.  In contrast to what observed in control BCLs, in patients, GH 
stimulation failed to induce phosphorylation of proteins of 90 kDa identified as 
belonging to the STAT molecules family, involved in the signal transduction through 
GHR.  In particular, after GH stimulation no phosphorylation of STAT5 protein was 
observed in γc negative patients cell lines in contrast to the control cells, in which a 
prompt activation of STAT5 occurred.  Of note, reconstitution of X-SCID cells with WT 
γc gene corrected the functional and biochemical abnormalities resulting in an 
appropriate nuclear translocation of STAT5.  These findings strongly support an 
essential role of γc in GHR signalling. 
STAT-dependent pathways are generally believed to be utilized in cellular events 
such as cell proliferation, differentiation and apoptosis (55, 56), even though the overall 
role of the STAT molecules in GHR signal transduction has not been fully elucidated.  
At least three different STAT family members (STAT1, STAT3 and STAT5) are 
activated following GHR perturbation (57-62), even though STAT5 seems to play a 
prominent role in receptor signaling.  Rodent models of STAT knockouts (63) and the 
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recent identification of a patient with a homozygous missense mutation of STAT5b gene 
indicate that STAT5b is essential for a normal postnatal linear growth (64).  
Furthermore, the patient with STAT5b mutation also had clinical features of immune 
deficiency such as chronic diarrhea and severe infections, including interstitial 
pneumopathy.  Immunologic studies showed hypergammaglobulinemia and markedly 
decreased IL-2Rα chain expression in response to IL-2 stimulation, suggestive of a T-
Cell activation defect.  Thus, a few features are similar to γc negative X-SCID patients.   
Although the activation of JAKs and STATs represents a prominent biochemical 
event during GH-dependent proliferation of lymphoid cell lines (65), other signaling 
pathways also contribute to a full GHR response.  GH has been shown to activate the 
phosphatidylinositol-3 kinase- (PI3 kinase)-protein kinase B signaling (66), mitogen-
activated protein kinases and extracellular regulated kinases 1 and 2 (ERK1 and 2) (67-
69).  In both STAT5 knockout mouse and in the patient with STAT5 mutation, these 
pathways are fully functional.  In keeping with this observation, also in our experimental 
model, no alteration was observed in ERK 1 and 2 expression and phosphorylation 
events involving JAK2, ERKs, STAT1 and 3 molecules that occur following GHR 
triggering. Moreover, in this study the involvement of PI3 kinase in GH-induced 
proliferation of BCLs was ruled out since the kinase inhibitor wortmannin was 
ineffective in blocking the proliferative response.  Similarly, IGF-I expression has been 
reported to be dependent on STAT5 b, but not on PI3 kinase pathway  (70). Taken 
together, these observations imply that GHR, as well as other receptors, is able to 
integrate different pathways which are individually differentially regulated.  In support 
of this, it has been recently shown that GHR signaling and the subsequent IGF-I 
transcription regulation are under different regulatory controls in hepatocytes, fibroblasts 
and myoblasts (71).  This could lead to hypothesize differential functions of an 
individual receptor exerted in different tissues.  A cell type-restricted STATs activation 
has been reported (72-74).  STAT5 is not activated following GH stimulation in human 
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fibrosarcoma cells even though these cells express the STAT5 protein (74), thus 
implying that a selectivity in the involvement of specific STAT subset seems to be a 
general feature of GHR signal transduction. 
Overall, activation of STAT5b is considered a prominent event in GHR signaling 
and is crucial for the regulation of transcription of GH-responsive genes, including the 
gene encoding for IGF-I.  This process relies on an appropriate phosphorylation and 
nuclear translocation of the molecule (42, 75).  Recently, it has been proposed that 
STATs tyrosine phosphorylation and nuclear translocation are two events that are 
regulated separately (54).  In particular, Giron-Michel J. and coworkers demonstrated in 
the hybrid receptor γc/GM-CSFRβ that γc/JAK3 complex controls the nuclear 
translocation of pSTAT5 rather than STAT5 phosphorylation itself (76).  Hence to 
address the issue of defining the functional implication of γc mutation on STAT5b 
activation, in our study, the subcellular localization of STAT5b was investigated by 
analyzing cytokine-induced translocation of STAT5b from the cytoplasm to the nucleus 
with confocal microscopy.  Stimulation with GH induced nuclear translocation of 
STAT5b in the control cells, whereas no efficient nuclear translocation occurred in γc 
negative cells.  Furthermore, immunoblot of nuclear and cytoplasmic extracts showed in 
control cells a rapid increase of the nuclear fraction of the STAT5 molecule after GH 
stimulation, which paralleled the molecule phosphorylation, differently from what 
observed in patient cells.  Moreover, through confocal microscopy studies, we 
demonstrated that GHR and γc co-localize, as expected in that both molecules are Type I 
hematopoietin receptors.  A physical interaction may be hypothesized as well, even 
though conclusive data are still lacking. 
Our data suggest that the γc chain is a required signaling subunit of the GHR 
complex in B cell lines.  In particular, in this cell line, it is selectively required for 
STAT5 phosphorylation and nuclear translocation, and not for the activation of other 
molecules as ERKs.   
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Our study demonstrates the existence of a previously unappreciated relationship 
between individually well studied elements, such as GHR and γc, and signaling 
pathways.  Crosstalk between receptor signaling systems is now emerging as an 
important and exciting area of signaling research.  Whether the participation of γc to the 
GHR confers some additional properties to the receptor in hematopoietic cell 
differentiation and functioning remains to be elucidated.  To note, in CD34+ 
progenitors, γc participates to hematopoietic cell differentiation by interacting with GM-
CSFRβ.  This interaction does not occur in normal natural killer cells or non 
hematopoietic cells (76).  Hence, the complexity of receptor signaling relies not only on 
the possibility that individual receptors interact one with each other, but also on a 
differential array of distinct subunits that may represent a hallmark of that specific cell 
type.  
Our current study also leads to explain what our group previously reported on an 
atypical X-SCID phenotype and severe short stature associated with growth hormone 
hypo-responsiveness and abnormal GHR induced protein tyrosine phosphorylation (19), 
and indicates that growth failure in X-SCID is directly related to the genetic alteration.  
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CHAPTER 2 
 
ROLE OF THE FOXN1 TRANSCRIPTION FACTOR IN THE DEVELOPMENT 
AND DIFFERENTIATION OF THE IMMUNE SYSTEM, NAIL AND CENTRAL 
NERVOUS SYSTEM. 
 
Introduction 
 
The thymus is a complex organ with a central role in the immune System, as it is 
crucially required for T-cell differentiation and repertoire selection.  The thymus 
consists of numerous lobules, each clearly divided in two main regions on histological 
ground an outer cortical region, the thymic cortex, and an inner medulla (77).  Each of 
these regions provides the unique combination of cellular interactions, cytokines and 
chemokines necessary to induce a particular aspect of thymocyte development (77-79).  
As thymocytes proliferate and mature into the T-cells, they pass through a series of 
distinct phase marked by changes in the status of T-cell receptor genes, and in the 
expression of the T-cell receptor, the co-receptors CD4 and CD8 and other cell-surface 
marker that reflect the state of functional maturation of the cells.  Thymocytes at 
different developmental stages are localized in distinct regions of the thymus.  Most of 
T-cell development takes place in the cortex whereas only mature T-cells are seen in the 
medulla (80, 81).  
Developing thymocytes undergo extensive selection to ensure that mature T cells 
exported from the thymus are functional and self-tolerant.  These processes are 
dependent on the interaction between thymocytes and thymic stroma and are termed 
positive and negative selection (82-86).  Positive selection is a consequence of whether 
the TCR on the developing lymphocyte is able to recognize self-peptide within the 
context of the self-MHC (87, 88).   Cells that cannot recognize the MHC:self-peptide 
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complex die by neglect.  In contrast, thymocytes with too high affinity for self-MHC 
peptide are deleted by negative selection, an active apoptotic process need to remove 
self-reactive clones (89).  The remaining thymocytes that respond whit low affinity are 
selected to develop into CD4+ or CD8+ single-positive cells (90-92).  Positive selection 
has been associated mainly with cortical thymic ephitelia cells (cTEC) and their 
associated MHC.  In contrast, negative selection of thymocytes has been reported to 
occur either in the cortico-medullary junction (CMJ) or in the thymic medulla (93, 94).  
A particular intriguing role for the medullary thymic epithelial cells (mTEC) in the 
induction on central tolerance recently emerged (95-97).  Organ-specific proteins are 
expressed in 1-5% of mTEC implicating a role in tolerance induction to a variety of 
tissues by the mTEC (84, 85, 97-99).  How such a rare population of cells could bring 
about large-scale tolerance is still to clarify.  A role of mTEC cells in the maturation of 
T regulatory cells was hypothesized (98).   Those thymocytes surviving selection mature 
in the medulla for an average of 14 days before thymic export towards the post-capillary 
venules at the CMJ (100).  The nature of the medullary maturation process is unknown. 
In the mouse, thymus anlagen arises as bilateral structures from the third 
pharyngeal pouch in the embryonic foregut (101, 102) and is colonized by 
hematopoietic progenitors in midgestation around embryonic day 11.5 (E11.5) (103).  At 
E11.5 the primordial thymic epithelial cells are yet incompetent to fully support T-cell 
development (103, 104).  In both human and mouse this essential capacity is dependent 
on the transcriptional activation of the FOXN1 gene in the thymic epithelium.  
FOXN1 gene, mapped on chromosome 17 in human and on chromosome 11 in 
mice, is composed of nine exons, of which exon 1 is non-coding (105).  Human and 
mouse FOXN1 genes show identical genomic structures, with the same number, 
location, phase and size of introns (105).  The genes located next to FOXN1 gene are 
also identical in both species.  FOXN1 has two alternative first exons that show tissue 
specificity and suggesting the existence of two different promotor sequences (105).  
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FOXN1 gene encodes for a member of the forkhead/winged helix class proteins, a large 
family of transcriptional factors that have been implicated in a variety of cellular 
processes (106, 107). Thus far, more than 100 members of this family have been 
identified.  The growth of the FOX family paralleled the increase in the overall 
knowledge on the importance of these molecules in the regulation of developmental 
processes.  FOX gene mutations have been found to be responsible for diverse 
phenotypes, ranging from alterations of craniopharyngeal development (FOXE1) to 
speech and language abnormalities (FOXP2) or hearing defects in mice (Foxi1) (108).  
Recessive mutations in the FOXN1 coding gene are associated with the mice 
“Nude” phenotype described for the first time by SP Flanagan (109-111).  In the 1966, 
Flanagan published his observation on a new “hairless” phenotype of mice lacking of fur 
development and with agenesis of the thymus associated with severe immunodeficiency 
(109, 112).  Today, the Nude mice are a widely use model in immunology, dermatology, 
cosmetic, oncological and transplantation research because of their defect in allo- or 
xeno-transplantation rejection due to the absence of a functional immune system (113, 
114).  Since the time of the first description of the Nude mice phenotype, more than 
30000 original papers in peer-reviewed journals have been published, and the number of 
publication using this model is growing year by year, confirming that this model 
represents a source of precious information for researchers (16).  Recently, we described 
a novel form of SCID caused by an intrinsic defect of the thymus (MIM 601705) in 2 
patients born to consanguineous parents originating from a small community in southern 
Italy. The hallmark of this human novel clinical phenotype is the congenital alopecia and 
a profound T-cell defect (17). This disease represents the human equivalent of the 
Nude/SCID murine phenotype (17).  In humans as in mice and rats (115), the 
Nude/SCID phenotype results from alterations of the FOXN1 gene (known in rats as 
Whn) (17, 18). The first described human FOXN1 mutation was a C792T transition in 
exon 5 resulting in the nonsense mutation R255X (18). This mutation lies upstream of 
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the DNA binding and transactivation domain of this transcription factor, so that 
translated protein, if any, would be completely non-functional, similar to the previously 
described rat and mouse Foxn1 mutations (116-118).  To date, the first two patients 
investigated, carrying the R255X mutation in the homozygous state, were born to 
consanguineous parents originating from a small community in southern Italy (17).  
Furthermore, from the community records 4 additional patients of previous generations 
were affected with congenital alopecia and died in early childhood because of severe 
infections.  Due to the geographical location of the village, lying in the mountains 
between Naples and Salerno, and the elevated rate of endogamy, the population may be 
considered isolated.   
In our study, based on the presence of several cases in the same community, a 
genetic screening for the presence of FOXN1 R255X mutation was performed in the 
attempt to identify an ancestral founder effect.  Moreover, we genotyped two 
microsatellite markers, D17S2187 and D17S1880, which flank the FOXN1 gene on 
chromosome 17 to define whether a founder chromosome is shared by subjects carrying 
the R255X mutation. Since FOXN1 seems to play a role in the regulation of the 
differentiation process of both cutaneous and thymic epithelial tissues (119, 120), an 
accurate physical examination of all subjects carrier for the identified FOXN1 mutation 
was also conducted in order to define whether the mutation in heterozygous state was 
associated with mild clinical signs. 
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Materials and Methods 
 
Sampling and participants 
 
All the living individuals still resident in the Acerno village and related to the 
probands' family were interviewed.  Information obtained from this survey was verified 
and integrated using the local church and community records dating back to 1800.  
Subsequently, all data were recorded and analyzed using the Cyrillic 3 software 
(Cherwell Scientific 2000, www.cyrillicsoftware.com V3.0.400).  After written informed 
consent, and upon approval of Institutional Ethical Committee, whole blood samples 
were collected from 843 subjects of the Acerno community, corresponding to 
approximately 30% of the population, and processed anonymously.  Samples were 
coded by a third party to allow re-testing of heterozygotes to confirm the result of the 
first determination. 
 
Mutation screening and sequence analysis 
 
Genomic DNA was extracted by salt precipitation method (121) from peripheral 
blood of the study subjects. A PCR fragment containing exon 5 of the FOXN1 gene was 
amplified using the primers: Exon 5F: 5'-CTTCTGGAGCGCAGGTTGTC-3' and Exon 
5R: 5'-TAAATGAAGCTCCCTCTGGC-3' (18).  PCR amplification resulted in a 184 bp 
product, containing 7 bp of intron 4, 131 bp of exon 5, and 46 bp of intron 5.  PCR was 
carried out according to the following protocol:  95°C for 5 minutes followed by 35 
cycles of 95°C for 45 seconds, 55°C for 45 seconds, and 72°C for 1 minute, and an 
extention step was performed at 72°C for 7 minutes in a Stratagene® RoboCycler® 
Gradient 96 thermal cycler (Stratagene®). PCR products were visualized after 
electrophoresis on a 2% agarose gel and purified in a first step using the High Pure PCR 
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product purification kit (Boehringer Mannheim).  Aliquots of the samples to be studied 
were digested with the restriction enzyme Bsr I and the product was electrophoresed on 
1.5% agarose gel.  PCR fragments positive to the digestion with Bsr I were then purified 
on Edge Centriflex columns (Edge BioSystems) and sequenced directly with POP-6 
polymer using an ABI Prism 310 Genetic Analyzer from Applied Biosystems Inc. 
(Perkin Elmer).  A second blood sample was drawn from subjects with the R255X 
mutation at the heterozygous state to confirm the result of the first determination. 
 
Clinical evaluation 
 
Physical examination of the identified heterozygous subjects was conducted paying a 
special attention to ectodermal abnormalities and, in particular, to alterations of hair and nails.  
These annexa were analyzed by at least 2 of us in the all the identified heterozygote carrier 
subjects, in 23 non heterozygous otherwise healthy married-in subjects, and 50 non 
heterozygous subjects belonging to the extended pedigree.  An accurate anamnesis was 
performed for each individual to evaluate any systemic disease able to induce nail dystrophy.  
Whenever necessary, cultures were performed to rule out mycotic infections.  Overt psoriasis 
was also excluded. 
Our pathologist performed fetus physical examination after written informed consent 
from the family and upon approval of Institutional Ethical Committee 
 
Marker typing 
 
Haplotype analysis was performed on 47 chromosomes carrying the mutation. 
According to the draft human genome sequence at UCSC (http://genome.cse.ucsc.edu/; 
December 2001 freeze), we chose microsatellite markers D17S2187 (GATA70H05) and 
D17S1880, located at 3.4 and 4.1 Mb centromeric and telomeric from the FOXN1 gene, 
respectively.  PCR primers for the microsatellite markers were obtained from the 
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Genome Database (http://gdbwww.gdb.org) and the Cooperative Human Linkage Center 
(http://gai.nci.nih.gov/CHLC). PCR conditions were as described above.  PCR amplification 
products were resolved on 6% non-denaturing polyacrylamide gel electrophoresis and 
visualized by ethidium bromide staining. 
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Results 
 
Identification of a founder effect for the R255X mutation described in the 2 patients with 
Nude/SCID immunodeficiency. 
 
 Fifty-five subjects, corresponding to 6.52% of the studied population, were found 
to be heterozygous carriers of the mutation.  Twenty-eight of them, corresponding to 
50.9%, were female.  These 55 subjects originated from 39 families, which were 
subjected to a genealogical study.  Through the archival database, common ancestors 
were identified for the 55 heterozygous subjects.  They are linked in an extended 7-
generations-pedigree comprising 483 subjects (Fig. 2.1), founded by a single ancestral 
couple born at the beginning of the 19th century.  In one family, heterozygotes were 
born to a mother who belonged to the pedigree but was found to be genotypically 
normal in two independent determinations.  The family name of the deceased father, 
who presumably transmitted the mutation, was one of the 6 recurrent surnames in the 
pedigree of the probands.   
 From the founding ancestral couple in the first generation, 4 family groups 
originated. All the affected cases belonged to this pedigree.  On the basis of our pedigree 
analysis, 33.3% of the mutation carriers inherited the mutated gene from their mother, 
whereas 66.7% inherited the mutant allele from their father.  The pedigree also shows a 
high rate of past and present consanguineous and endogamous matings, typical of small 
communities.  In particular, 14 out of 151 marriages were found to be consanguineous.    
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Figure 2.1 Seven generations pedigree including the Acerno families linked to the index family.  
Not all relatives are shown, but only the subjects necessary to demostrate the founder effect.  Filled 
circles indicate affected individuals.  Half-filled symbols indicate heterozygous carriers of the mutation 
R255X.  The arrow indicates the proband.  
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 To confirm that the R255X mutation represents a single ancestral event, we 
constructed the haplotype for the FOXN1 locus for 47 chromosomes carrying the 
mutation R255X.  The haplotype for D17S2187-FOXN1-D17S1880 could be established 
for 27 carrier chromosomes and three different haplotypes were identified: 3-R255X-3 
(14/27), 3-R255X-2 (11/27) and 3-R255X-1 (2/27) (Table 2.I).  The same haplotypes for 
the microsatellite markers (D17S2187-D17S1880) were identified in just 1 (3-3), 5 (3-2) 
and 6 (3-1) non-carrier chromosomes.  Among the carrier individuals for whom the 
phase could not be established (20/47), 3 and 2 were consistent with haplotypes 3-3 and 
3-1, respectively, whereas 10, 2 and 3 were consistent with two of the previous 
haplotypes, 3-3/2, 3-3/1 and 3-2/1, respectively.  Assuming recombination over the 
generations, these haplotypes could be consistent with a single ancestral origin of 
mutation R255X in the Acerno population. 
 
 
Table 2.I.  Haplotypes analysis  
 R255X carrier chromosomes 
Haplotype Known fase Unknown fase 
3-R255X-3 14/27 3/20 
3-R255X-2 11/27 - 
3-R255X-1 2/27 2/20 
3-R255X-3/2 - 10/20 
3-R255X-3/1 - 2/20 
3-R255X-2/1 - 3/20 
 
 
Identification of clinical signs associated with heterozygous mutations in the FOXN1 
gene 
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 It is well known that loss of function mutations of FOXN1 gene are characterized 
in the both human and mouse Nude/SCID phenotype by the abnormal morphogenesis of 
epidermis, hair follicles and thymus (119).  
Since this, the physical examination of the R255X heterozygous subjects was 
performed paying a special attention to ectodermal abnormalities and, in particular, to 
alterations of hair and nails.  No gross alteration of the hair was noted in association with 
the heterozygosity.  Differently, nail examination revealed that 39 out of the 55 
heterozygous subjects showed a nail dystrophy.  This finding was not observed in any of 
23 not heterozygous otherwise healthy married-in subjects, and 50 not heterozygous 
subjects belonging to the same extended pedigree examined.  Accurate anamnesis and 
cultures were performed to exclude any possible acquired form of nail dystrophy and to 
rule out mycotic infections. Overt psoriasis was also excluded.   
 The identified pattern of the phenotypic alteration of the nails was variable (Fig. 
2.2).  The koilonichia or "spoon nail" characterized by a concave surface and raised edges 
of the nail plate associated with a significant thinning of the plate itself were the more 
frequent alteration.  Koilonichia was found in 28 subjects, whereas the canaliform 
dystrophy and a transverse groove of nail plate (Beau's line) were found in 13 and 11 
subjects, respectively (Table 2.II).  It is note worthy that the more specific phenotypic 
alteration was the leukonychia characterized by a typical arcifom pattern, involving the 
proximal part of the nail plate reminiscent of the half-moon.  This is not surprising since it 
reflects an abnormal differentiation process of the cells of the matrix.  Seventeen out of 
the 39 heterozygotes with nail dystrophy had 2 or more features.  It should be noted that 
in 18 cases fingernails and toenails were both affected, whereas in 4 subjects the 
dystrophy was only observed in the feet. 
 
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Nail dystrophy pattern in subjects heterozygous for the FOXN1 mutation. (A) Koilonychia. 
(B) Canaliform dystrophy. (C) Leukonychia. 
A 
B 
C 
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Table 2.II.  Pattern of nail dystrophy in R255X heterozygous subjects 
Nail alteration localization Pattern of Nail 
dystrophy 
N° of 
Patients Hand Feet 
Leukonychia 6 5 3 
Koilonychia 28 23 18 
Canaliform   
Onycodystrophy 
13 12 2 
Beau’s line 11 10 6 
 
 
 
Unexpected phenotype of a human Nude/SCID fetus homozygous for the nonsense 
R255X mutation in exon 5 of the FOXN1 coding gene 
 
 During the population study an affected female fetus homozygous for the R255X 
mutation was identified, thus leading to a medical interruption of pregnancy. Fetus 
underwent physical examination by our pathologist in order to define whether FOXN1 
homozygous alteration was associated with defects in the differentiation process and 
fetus development. 
 The pathology examination revealed that, identical to the Nude/SCID phenotype 
of mice, the affected human fetus lacked a thymus (Figure 2.3A), confirming that 
FOXN1 is essential for thymic development also in humans.  As previously reported in 
mice model (109, 119), the skin appeared grossly abnormal, being more tight than usual.  
The histology of the skin revealed basal hyperplasia and dysmaturity suggestive of an 
impaired differentiation program. In addition, the fetus had multiple-site neural tube 
defects, including anencephaly and spina bifida (Figure 2.3B, C).  While there have been 
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no prior studies of FOXN1 activity in the nervous system, we observed that the Foxn1 
gene is expressed in murine epithelial cells of the developing choroid plexus, a structure 
filling the lateral, third, and fourth ventricles of the embryonic brain (Figure 2.4).   
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Figure 2.3.  Morphological phenotype of FOXN1-/- human.  The skin was tight, shiny and 
smooth.  (A) Ventral view of the fetus showing the absence of thymus in the chest.  The arrow 
indicates the usual thymus location. (B) Dorsal view showing the skull of the FOXN1-/- fetus.  
Complete anencephaly characterized by the absence of scalp, calvarium and brain.  (C) Dorsal 
view showing the craniospinal rachischisis. nt*, open neural tube (spina bifida). 
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Figure 2.4.  Foxn1 expression in the brain of E15.5 murine embryos.  A β-galactosidase 
reporter gene was inserted into the Foxn1 locus by homologous recombination (110).  
Heterozygous embryos (Foxn1+/Foxn1lacZ), which are phenotypically normal, were stained for 
β-galactosidase activity (blue) as described  (119).  Foxn1 is expressed throughout the 
epithelium of the developing choroid plexus. (scale bar represents 50 4m).  (Figure provides us 
by our collaborator Doc Brissette J.L.) 
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Discussion 
 
Reported data demonstrate that the FOXN1 mutation R255X, which underlies the 
human equivalent of the murine Nude/SCID phenotype, is present in the heterozygous 
state in the Acerno population, and seems to have a single ancestral origin, dated to the 
early 19th century.  An extended pedigree, including most of the heterozygous subjects 
in the population, was constructed on the basis of genealogical data.  The prevalence of 
the carriers in this community was of 6.52% thus leading to a presumptive estimate of 
expected new cases, in the absence of prenatal diagnosis, of 1:1000 live births.  This 
estimation does not take into account the elevated frequency of the carrier status within 
the extended pedigree, which corresponds to 36.9%, and, more importantly, the elevated 
rate of consanguineous matings among the families, which have occurred on several 
occasions in the last century. 
 Identification of a large pedigree in an isolated population is suggestive of a 
common allelic variant that are likely to have the same ancestral origin.  Indeed, analysis 
of microsatellite markers D17S2187 and D17S1880 identified three haplotypes, 
3/R255X/3, 3/R255X/2 and 3/R255X/1. Assuming recombination over the generations, 
these haplotypes could be consistent with a single ancestral origin of mutation R255X in 
the Acerno population. Our findings further support that all carrier chromosomes derive 
from a single ancestral chromosome on which the mutation arose in the conserved 
haplotype.   
Nude/SCID immunodeficiency is particularly devastating due to the absence of 
the thymus, and because stem cell based therapies cannot provide a cure, as they can in 
the other forms of SCIDs. Thus, the importance of genetic counseling of couples at risk 
and of first trimester prenatal diagnosis by direct genetic analysis, given the high 
frequency of FOXN1 mutation in the Acerno population cannot be overemphasized.  It is 
remarkable that although a screening program for prenatal diagnosis has only been 
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introduced for a short period of time in Acerno, an affected female fetus could already 
be identified, thus indicating the usefulness of this effort in an isolated community.  
 Perhaps, in the near future innovative therapeutic strategies as thymic 
transplantation, already successfully performed in DiGeorge syndrome, could be proven 
helpful in treating this form of SCID in affected individuals. 
 Clinical examination of subjects related to the 2 identified Nude/SCID patients 
shows that nail dystrophy is frequently associated with heterozygous mutations in the 
FOXN1 gene. This finding is in keeping with the alterations of digits and nails reported 
in a few strains of nude mice (119).  Since the nail plate originates mainly from the nail 
matrix and FOXN1 is selectively expressed in such structure, our observation confirms 
that this transcription factor is involved in the maturation process of nails, and suggests 
that this sign may be indicative of heterozygosity for this molecular alteration.  Our 
observations were independently confirmed in the mouse model by L Mecklenburg and 
colleagues, which demonstrated the association between the nude mice severe 
onychodystrophy and alterations of the onycholemmal differentiation pattern (122).  
As previously reported, this form of SCID is particularly severe due to the 
absence of the thymus. Thus, the importance of genetic counseling of couples at risk and 
of first trimester prenatal diagnosis by direct genetic analysis, given the high frequency 
of FOXN1 mutation in the Acerno population cannot be overemphasized.  It is 
remarkable that although a screening program for prenatal diagnosis has only been 
introduced for a short period of time in Acerno, an affected female fetus could already 
be identified, thus indicating the usefulness of this effort in an isolated community.  
The pathological examination of the homozygous FOXN1 mutated fetus suggests 
that FOXN1 may be involved in the brain and neural tube development and function in a 
similar fashion to other members of the forkhead/winged helix class proteins, such as 
murine HNF-3β and BF-1 (123), and human FOXP2 (124).  Mice defective in HNF-3β 
through gene targeting technology lack notochord which results in severe defects of the 
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neural tube organization (123).  Similarly in humans, alterations in the FOXP2 gene 
were associated with neurodevelopmental disorders, suggesting that the molecule has a 
key role in neural functioning (124).   
Furthermore, as the choroid plexus modulates the composition of the 
cerebrospinal fluid, transporting or secreting key molecules into the brain’s 
environment, it is thought that plexal cells have profound effects on the morphogenesis 
of neural structures (125).  Thus, the expression of Foxn1 in the embryonic choroid 
plexus is consistent with a possible role of Foxn1 in the development of the central 
nervous system.   
Moreover, there are a few considerations that suggest that the association between 
the Nude/SCID mutation and anencephaly may be causally related.  First of all, other 
forms of SCID become clinically evident during the first months of postnatal life, when 
the protection of the newborn by the mother immune system declines.  Congenital 
SCIDs are not related to increased spontaneous interruption of pregnancy.  In the 
community where the human Nude/SCID was discovered, there is a high rate of 
abortions in the first trimester in the marriages between subjects heterozygous for the 
FOXN1 mutation.  This finding suggests that FOXN1 may also be implicated in the 
development, since the first trimester mortality is not justified by the SCID per se.  
Furthermore, even though there is not any demonstration that in mice there are grossly 
brain malformations, it has been reported in Nude/SCID mice a reduced number of 
Purkinje cells of the cerebellum, which in addition is reduced in size (126).  
Furthermore, a high prevalence of perinatal death was reported in the spontaneous strain 
"nude Yurlovo" (127).  It is to note that organogenesis in mice lasts all the pregnancy, 
while in humans it mainly occurs in the first 3 months.   
A possible explanation of the reported features is that an impaired ectodermal 
development with a consequent defective epidermis overlying the neural folds 
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differentiation may have prevented the neural folds from coming together to form the 
neural tube causing anencephaly and spina bifida.   
The association herein reported in man, indicating that the human phenotype is 
more severe than in mice, could also explain the reason by which the human counterpart 
of the mouse Nude/SCID, described in 1966, has only been identified 30 years later 
(17).  Further studies may be planned to define whether a more severe clinical 
expression of the Nude/SCID may lead to prenatal lethality and a milder one to a 
newborn with Nude/SCID. 
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CHAPTER 3 
 
INTERLEUKIN-12 RECEPTOR BETA 2 CHAIN GENE (IL-12RB2) SINGLE 
NUCLEOTIDE POLYMORPHISMS AND ELEVATED SERUM IGE LEVELS 
IN CHILDREN. 
 
Introduction 
 
Interleukin-12 (IL-12) is a proinflammatory cytokine that plays a critical role in 
cellular mediated immunity against intracellular pathogens, such as Mycobacteria and 
Salmonella (128). 
The inflammatory response triggered by pathogens is characterized by recruitment 
of inflammatory cells, alteration in vascular permeability and production of soluble 
mediators, such cytokine, chemokine and interferons (129).  The first response of the 
immune system, innate or specific, is induced by binding of bacterial an microbial 
ligands to surface receptors expressed on macrophages and dendritic cells and evolved 
to recognize and bind common constituents of many bacterial surface.  Bacterial 
molecules binding to these receptors trigger the cells to engulf the bacterium and also 
induce secretion of biologically active molecules by macrophages and dendritic cells 
(129).  The development of an effective innate response to pathogen infections is 
necessary to prevent or control infections, but is ultimately instrumental for the 
consequential adaptive immune response, required to complete elimination of pathogens 
and establishing of memory.  The soluble mediators released during the innate response 
are then critical to regulate and drive the adaptive immune response, mainly guiding the 
migration of antigen-specific T lymphocytes to lympho nodes, where they interact with 
antigen-presenting cells (APC) (129).  This will results in activation and expansion of 
antigen-specific T lymphocytes, resulting in a response of T helper 1 (Th1) or T helper 2 
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(Th2) type, depending on the intracellular or extra-cellular nature of the pathogen, 
respectively (130).  Different pathogens will induce the production of distinct patterns of 
cytokines and mediators, finally driving T cells towards either Th1 or Th2 phenotype, 
which are characterized by the ability to secrete different cytokines, resulting in a 
adaptive immune response cell or antibodies mediated, respectively (130).  The main 
cytokine involved in directing T cells towards Th1 phenotype has been demonstrated to 
be IL-12 (131, 132), while IL-4 drives Th2 phenotype development (133). 
IL-12 is a heterodimeric cytokine composed of a 40 kDa (p40) and 35 kDa (p30) 
subunits secreted by mature dendritic cells, neutrophils and macrophages (134-136).  
The p40 subunit is homologous to other members of the cytokine-receptor family, while 
p35 is homologous to other single chain cytokine, such as IL-6 and G-CSF (137).   IL-12 
mediates its biological activities through a specific surface receptor (IL-12R) consisting 
of two polypeptide chains, β1 and β2.  Both subunits belong to the class I cytokine 
receptor superfamily and are homologous to cytokine receptor glycoprotein (gp)130 
(138-140).  IL-12 p40 subunit interacts mainly with IL-12Rβ1 chain, while p35 binds to 
IL-12Rβ2 chain.  In the human system, IL-12Rβ1 and β2 chains alone have low affinity 
to IL-12 and they both are required to form high-affinity IL-12 binding sites (141).  In 
contrast in mouse system, IL-12Rβ1 is primarily responsible for the high-affinity 
binding of IL-12.  In both systems, IL-12Rβ2 chain is responsible for signal 
transduction: indeed it contains 3 tyrosine residues, whose phosphorylation activates the 
intracellular signaling cascade (142). 
IL-12R is mainly expressed on the surface of activated T and NK cells (142), but 
it is also found on DC’s (143) and B cells (144).  IL-12 expressed a low levels in resting 
T cells is up-regulated following activation of T cells through TCR, and further 
increased by IL-12 itself, IFN-α, IFN-γ, TNF and CD-28 co-stimulation (129).  The 
expression of IL-12Rβ2 is highly regulated and is crucial in conferring responsiveness to 
IL-12.  Only Th1 cells retain IL-12Rβ2 expression and consequently can respond to IL-
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12, while Th2 cells down-regulate IL-12Rβ2 loosing the ability to respond to IL-12 
(145).  In Th1 cells, the IL-12Rβ2 expression is mainly maintained by IFN-γ-mediated 
up-regulation of the transcription factor T-bet (146).  In contrast, in Th2 cells IL-4 
inhibits IL-12Rβ2 expression (147). 
Upon binding of IL-12 to its receptor, receptor-associated protein tyrosine kinases 
of the Janus kinases family (JAKs) (32), namely JAK2 and TYK2, are activated by 
transphosphorylation (148, 149).  JAK2 and TYK2 in turn phosphorylated the 3 tyrosine 
residues on the intracellular portion of IL-12Rβ2, creating a docking site for the 
transcription factors Signal Transducers and Activators of Transcription (STATs).  
STATs bind to the receptor chain and get in turn phosphorylated by JAKs.  
Phosphorylated STATs homo- or hetero-dimerize and translocate in the nucleus, where 
they regulate gene transcription.   Although STAT1, STAT3 and STAT5 have been 
reported to be activated in response to IL-12 (142), the specific functional effects of IL-
12 are mainly due to the activation of STAT4 (129). 
Even though IL-12 stimulates proliferation of hematopoietic precursor cells and 
of activated T and NK cells, its principal function is the strong induction of IFN-γ 
production.  
Both IL-12 and IFN-γ suppress IgE synthesis and inhibit the development of Th2 
cells (150).  Allergic disorders are thought to be associated with a predominant Th2 
activity, usually involved in the response to extra-cellular pathogens (151).  
Furthermore, accumulating evidence indicates that a defective Th1 response is 
associated with elevated antigen specific IgE levels (152).  Mice lacking IL-12 or IL-
12R chains exhibit poor Th1 and enhanced Th2 responses (153-155).  Mutations of IL-
12R beta 2 gene were reported in adult atopic subjects (156, 157) as well as 
polymorphisms of FceRIIB and IL-4R coding genes.   
Thus, to verify the possible association between enhanced Th2 response and IL-
12Rβ2 coding gene (IL-12RB) single nucleotide polymorphisms (SNPs) in childhood, a 
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systematic search for nucleotide variations in the gene coding for this receptor chain was 
performed in a cohort of atopic patients with elevated serum IgE level and healthy 
control.  Allelic frequency of each identified polymorphism was calculated in the control 
group and in atopic patients divided in two subgroups according to the serum IgE level.  
Recently, Ober et al (158) have reported data suggesting that the study of haplotypes at 
multiple loci in a gene could be more informative than the separate study of separate 
SNPs.  To test the relationship between IgE value and IL-12RB2 polymorphisms 
haplotype analysis was also performed.  
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Materials and Methods 
 
Patients 
 
Patients with elevated serum IgE levels (53 unrelated individuals with a mean age 
of 8.38 + 3.34 years; 29 male) met the following inclusion criteria: High serum IgE 
levels (Total serum IgE> mean value for age + 2SD), absence of typical clinical and 
immunological features for Hyper-IgE Syndrome (159).  The main clinical features of 
the patients were reported in Table 3.I.  
 
Table 3.I.  Clinical features of the patients 
  Number of patients 
according to serum levels 
Main clinical features Number of patients <2000 U/ml >2000 U/ml 
Asthma 27 15/34 12/19 
Rhinitis/Conjunctivitis 12 5/34 7/19 
Eczema/Atopic Dermatitis 11 6/34 5/19 
Urticaria 15 8/34 7/19 
 
 
Patients were divided on the basis of the IgE levels in 2 subgroups: group A consisted of 
children with serum IgE levels > 2000 kU/l and group B of children with IgE levels > 
mean value for age + 2SD < 2000 kU/l. Fifty healthy unrelated control subjects were 
randomly selected.   
The protocol was approved by the local ethics Committee, and informed consent 
from all individuals was obtained.   
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Genomic DNA isolation. PCR amplification and exons sequencing 
 
DNA was isolated from peripheral white blood cells using the salting-out method 
(121).  IL-12RB2 gene exons were amplified by 30 cycles of PCR using the specific 
primers listen in Table3.II:  
Each amplified product was run on a 1.8% agarose gel with a size marker (1 kb 
DNA ladder M-Medical GENENCO - Life Science). These fragments were purified 
from gel using Gel extraction kit (QIAquick) and sequenced in an automatic DNA 
sequencer (ABI 377 DNA sequencer, Applied Biosystems).  
 
Statistical analysis 
 
The association between the IL-12RB2 gene polymorphisms and IgE levels was 
investigated by comparing each allele rate in patients and controls groups by Pearson χ2 
test. 
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Table 3.II:  IL-12R primers 
Name Sequence (5’- 3’) 5’-Position 
1PRB2L 5’-tgttgagaaagcattgtta-3’ Promotore 
2PRB2R 5’-cttccatttgtatttgctgt-3’ Promotore 
PRB2L5’A 5’-tcacaatcccataaagacaa-3’ Promotore 
PRB2R3’ 5’-aactgccaggtaaacaataa-3’ Promotore 
EX1L5’ 5’-agacagcaaatacaaatgga-3’ Esone 1 
EX1R3’B2 5’-gagacgcgagacacgcaatc-3’ Esone1 
1EX1L5’B2 5’-actccagtgggcggtcttct-3’ Esone 1 
2EX1R3’B2 5’-cgaggtgaggtgcgtttatg-3’ Esone 1 
EX2L5’B2 5’-gctattttggctctggtatt- 3’ Esone 2 
EX2R3’B2 5’-actacaaaagaccaactacc-3’ Esone 2 
EX3L5’B2 5’-ttaattttaccctgttttgg-3’ Esone 3 
EX3R3’B2 5’-aatgctcaccaccaacgaag-3’ Esone 3 
EX4LB2 5’-aggttttgtcttttcttttt-3’ Esone 4 
EX4RB2 5’-aatacagcctctcactcact-3’ Esone 4 
EX5LB2 5’-attttgttcttttctactgt-3’ Esone 5 
EX5RB2 5’-aatgaaacagtgaaataaaa-3’ Esone 5 
EX6LB2 5’-tttgtttgtcctggttcata-3’ Esone 6 
EX6RB2 5’-cttcagtgttttttccttca-3’ Esone 6 
EX7LB2 5’-taggtgtgaaaaacaa-3’ Esone 7 
EX7RB2 5’-gatcaaacaggagtttg-3’ Esone 7 
EX8LB2 5’-cctttgaaacagagcctact-3’ Esone 8 
EX8RB2 5’-gttttattcccttgagtttt-3’ Esone 8 
EX9LB2 5’-gtctgggagtaaatagtgaa-3’ Esone 9 
EX9RB2 5’-aagagatgagtaagacacag-3’ Esone 9 
EX10LB2 5’-ttttgtttctcctctttctg-3’ Esone 10 
EX10RB2 5’-tccccaaacaaatgtgaact-3’ Esone 10 
EX11LB2 5’-gaaagcatttgtatcagata-3’ Esone 11 
EX11RB2 5’-tgtcaacctccaaatccaaa-3’ Esone 11 
EX12LB2 5’-cctcctgtgccctactttac-3’ Esone 12 
EX12RB2 5’-acctccttgtgttttcctga-3’ Esone 12 
EX13LB2 5’tatgctgtggagtggagtgag-3’ Esone 13 
EX13RB2 5’cagagttttgagtaggcgtatg-3’ Esone 13 
EX14LB2 5’-tcctttctgaccctggct-3’ Esone 14 
EX14RB2 5’-ccaggaatgtgtgagagc-3’ Esone 14 
EX15LB2 5’-ctttgtctttcag ttcgat-3’ Esone 15 
EX15RB2 5’-tagggggttttagttc-3’ Esone 15 
EX16LB2 5’-ctcaggagaagaagacac-3’ Esone 16 
EX16RB2 5'-ttgaggggaaaacagaaagg-3' Esone 16 
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Results and Discussion 
 
Two newly identified SNPs, one G2569A in the exon 14 and the other A2977C in 
exon  16  of  IL-12RB2  gene  were  found.  G2569A polymorphism maps in the  
transmembrane region, while the A2977C SNP maps in the Box 2 domain of the beta  2 
chain.  Both of them did not result in a change in the aminoacid sequence.   
 
 
Table 3.III.  IL-12 SNPs frequency in overall patients group and controls 
 
Allele frequency 
Controls 
(n = 50) (%) 
Patients 
(n= 53) (%) 
 
OR 
 
95% CI 
 
P 
G2569A 27 36 1.52 0.83-2.77 0.1707 
A2977C 29 41.9 1.77 0.99-3.19 0.0547 
 
 
Frequency of  G2569A  and  A2977C  SNPs  did  not  differ  significantly between 
patients and controls when the overall group of patients was  analyzed ( p = 0.1707 and 
p = 0.0547, respectively) (Table 3.2).   
However, when the patients were divided on the basis of IgE levels as specified in the 
method section, in the group A a significantly higher frequency of A2977C SNP than 
controls was observed  (odds ratio [OR], 1.85; 95% CI, 1.03-3.32; p = 0.039) (Table 
3.3).   
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Table 3.IV.  IL-12 SNPs frequency in patients with IgE serum levels .2000 U/ml 
(group A) and controls 
 
Allele frequency 
Controls 
(n = 50) (%) 
Patients 
(n= 19) (%) 
 
OR 
 
95% CI 
 
P 
G2569A 27 36 0.95 0.71-1.34 0.87 
A2977C 29 41.9 1.85 1.03-3.32 0.039 
 
Recently, Ober et al (158) reported data suggesting that the analysis of haplotypes at 
multiple loci in a gene could be more informative than the analysis of a separate SNP.  
Thus, to test the relationship between IgE levels and IL-12RB2 SNPs, haplotype 
analysis was also performed.  The genotype carrying both alleles in the reference 
sequence, referred as  "wild-type allele", was significantly more expressed in the control 
subjects than in patients (29.2 vs 7.5%; p < 0.001).  By contrast, in the patients' group 
15.1% was homozygous for the A2977C SNP as compared to the 4.2% of controls (p < 
0.008).  
In conclusion, differently from what previously reported on adult patients, we 
could not find any mutation of IL-12RB2 gene in atopic children, but two new SNPs, 
2569G/A and 2977A/C, mapping in the exon 14 and exon 16, respectively.  The 
frequency of 2977A/C SNP was more represented in atopic children.  Since no 
aminoacid change occurred, this alteration would represent a molecular marker, 
suggesting a role in atopy of a gene in close linkage disequilibrium with the reported 
SNPs. 
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CONCLUSIONS 
 
Human body, with its multitude of complexities, requires harmonious interaction 
among all its constituents for the maintenance of homeostasis.  Because every member 
of this intricate community has its own “agenda”, a peaceful and productive interaction 
between them is not trivial. 
Communication between and within cells is essential for the development and 
survival of any complex organism.  Homeostasis in the living organism is due to the 
capacity of several systems to participate in complex networks and to exchange 
information through cell-to-cell interactions and soluble chemical mediators.     
The human Immune System (IS), allows the human body to respond to foreign 
invaders (bacteria, viruses and other infectious agents) and stressed cells and is the 
prototype of this type of network.  The interactions between specialized cells of the IS 
and different organs are tightly regulated.  Cytokines, hormones and cell-to-cell 
interactions ensure that the immune cell repertoire is sufficiently devoid of cells that 
could cause harm to self, while maintaining a wide selection of those that are adept to 
taking appropriate action against non self.  Furthermore, chemical messengers and 
physical interaction between different cell populations participate in the active 
regulation of the immune response.  These checks and balances are essential to maintain 
homeostasis. 
In the last twenty years of the 20th century, many scientific papers have been 
published on the molecular and cellular basis of the immune response and on the 
mechanisms involved in the correct development of immunological diversity and self-
tolerance.  The product of such studies is formidable.  Today, we know the structure of 
the main molecules involved in the discrimination between self and non-self and we can 
discern between different cell subpopulations involved in the immune response.  
Furthermore, we are expanding our knowledge of the genetic and molecular basis of 
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differentiation and biochemical processes.  Less is currently known about the 
mechanisms involved in the regulation of these processes, about how the cells of the IS 
and their products interacts with the other components of the organism, and about the 
consequences of these interactions. 
During the four years of my PhD program I have contributed to the definition and 
characterization of these interactions.   
Studying a group of atypical patients with X-SCID I could demonstrate for the 
first time a previously unappreciated functional interaction between the GHR apparatus 
and the γc chain.  Our study also indicates that growth failure in X-SCID is directly 
related to the genetic alteration and not only to the immunological status of patients.  
The identification of unexpected neurological defects in a fetus homozygous for the 
R255X mutation in the FOXN1 gene, responsible for the human Nude/SCID phenotype, 
for the first time suggests that FOXN1 may be involved in the brain and neural tube 
development and function.  This observation can explain the high rate of abortions in the 
first trimester in the marriages between subjects heterozygous for the FOXN1 mutation, 
whereas other congenital SCIDs are not related to increased spontaneous interruption of 
pregnancy.  Furthermore, the involvement of FOXN1 in the development observed, 
indicating that the human phenotype is more severe than in mice, could also explain the 
reason by which the human counterpart of the mouse Nude/SCID, described in 1966, 
has only been identified 30 years later.   
Overall, all my studies underlay the close interaction between different biologic 
system in a complex regulatory network. 
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